Drug - International Biopharmaceutical Industry

news

Biogen, having scrapped Aduhelm, tries to convince investors of turnaround plan

Biogen’s drug for Alzheimer’s disease, once considered a blockbuster-in-waiting, has run into so many obstacles since gaining approval last June that the company is n...

9 May 2022 news Aduhelm | Alzheimer

Continue Reading →

news

AstraZeneca and Daiichi set to broaden use of breast cancer drug, challenging Roche

Dive Brief: The Food and Drug Administration approved the antibody treatment Enhertu for earlier use in breast cancer patients, the latest milestone for a drug tha...

9 May 2022 news AstraZeneca | breast

Continue Reading →

news

Lilly’s closely watched diabetes drug scores in obesity trial

Dive Brief: Eli Lilly’s experimental diabetes shot tirzepatide helped obese people who have an underlying medical condition lose more than 15% of their body weight...

29 April 2022 news diabetes | Drug

Continue Reading →

news

Novartis names longtime analyst as top dealmaker amid organizational shakeup

Dive Brief: Novartis on Tuesday named Ronny Gal, a longtime analyst with advisory firm Bernstein, as its chief strategy and growth officer, the latest move in an o...

28 April 2022 news company | dealmaker

Continue Reading →

news

FDA sets back Novartis’ best chance at a COVID-19 drug

Dive Brief: Novartis is reevaluating its commitment to an experimental COVID-19 treatment originally developed by fellow Swiss drug company Molecular Partners afte...

28 April 2022 news Amgen | COVID-19

Continue Reading →

news

Drug price hikes moderate as rebates rise, report finds

Dive Brief: List prices of branded drugs in the U.S. rose by an average of nearly 5% last year, according to a report released Thursday by Iqvia, a consultancy and...

25 April 2022 news COVID-19 | Drug

Continue Reading →

news

A promising cancer drug leads Regeneron to reconsider its aversion to M&A

Dive Brief: Regeneron has agreed to purchase a young biotechnology company for access to a drug that the buyer believes will be a valuable component in cancer-figh...

25 April 2022 news biotechnology | cancer

Continue Reading →

news

Seagen to expand, add jobs with new cancer drug factory

Dive Brief: Seagen, the largest biotechnology company in the Seattle area, has unveiled plans for a manufacturing facility to help provide "greater control and fle...

25 April 2022 news cancer | Drug

Continue Reading →

news

Biogen pulls European application for Aduhelm in another setback for the Alzheimer’s drug

Dive Brief: Biogen has withdrawn a request to start selling its Alzheimer's disease drug in Europe, marking the latest setback in the company's efforts to ramp up ...

25 April 2022 news Aduhelm | Alzheimer

Continue Reading →

news

GSK acquires Sierra Oncology, betting $2B on a bone cancer drug with a long history

GlaxoSmithKline has agreed to acquire Sierra Oncology for $1.9 billion in a bet that an experimental drug the small biotech developed is on the cusp of becoming a val...

14 April 2022 news cancer | Drug

Continue Reading →